AIxplorerBio is an AI-powered drug R&D biotech company. We focus on the discovery and development of new medicines for immunological and neurodegenerative diseases. We are also committed to creating a new AI-powered drug R&D paradigm to enable innovation, efficiency and precision in searching for better medicines.
AIxplorerBio is established by a team of highly experienced cross-discipline experts and sponsored by the new B/IT (biotechnology and information technology) powerhouse, BioMap, and the leading drug discovery CRO platform, Viva Biotech. In addition to the strategic cooperation with BioMap and Viva, AIxplorerBio also actively seeks collaboration opportunities with AI-oriented technology companies as well as drug R&D companies to explore more efficient ways for new drug R&D.
Founder / CEO
Dr. David Xu has over 20 years of experiences in drug R&D and business operations. Prior to creating AIxplorerBio, Dr. Xu was the CBO at Viva Biotech Holdings, where he helped build up the company’s investment and incubation business and was responsible for investing in over 50 startup companies. Before his returning to China, Dr Xu was the Head of Marketing and New Product Planning functions at Purdue Pharma in the US. Dr. Xu started his pharmaceutical career with Novartis Pharma in the US as an R&D chemist and cultivated his 20 years of tenure at Novartis with broad and increasing responsibilities, including Head of Specialty Product Franchise at Sandoz (a Novartis company), Head of Chemical R&D at Novartis China.
Dr. Xu has a B.S. in Chemistry from Peking University; Ph.D in Chemistry from UCLA; and an MBA from the Wharton School of Business, University of Pennsylvania. He also did his Post-doc at The Scripps Research Institute.
Professor Yang is well known for his expertise and contributions in developing algorithms for biomedical big data analysis and drug AI design. Dr. Yang has ranked top in international protein structure prediction and genome interpretation competitions for many times. He has developed dozens of bioinformatics software that are widely used worldwide.
Since 2017，Professor Yang has been a Professor at the School of Computer Science and Engineering at Sun Yat-sen University and the Deputy Principle Engineer at the National Supercomputer Center at Guangzhou, China
Prior to his current role, he was a Research Fellow at the School of Information and Communication Technology & Institute for Glycomics, Griffith University, Australia. He did his post-doc research and subsequently served as a Research Assistant Professor at the School of Informatics & School of Medicine, Indiana University, USA.
Professor Yang received his B.S. in Biology and Ph.D. in Computational Biology, both from the University of Science and Technology of China.
Senior Vice President
Dr. Xue has more than 20 years of experience in chemo-and bio-informatics as well as computer aided drug discovery (CADD).
Prior to joining AIxplorerBio, Dr. Xue was Executive Director and the Head of Computational Chemistry and Informatics of the IDSU business unit at Wuxi PharmaTech. Before assuming the position at Wuxi Pharma，Dr. Xue had been working in various roles in the US with both MNCs as well as Biotech startup companies.
Dr. Xue received his B.S. in Organic Chemistry from Fudan University and his Ph.D. in Chemistry from University of Iowa. He also has a M.S. degree in Computer Science from University of Iowa.
The rapid advancement in AI technologies, the fast accumulation of “omics” data and the expanding structural information of proteins, etc. are opening up new possibilities for drug discovery. AIxplorerBio intends to capitalize on these technology advancements to design and develop the right medications for the right patients faster, at scale and with higher success rate.
We will build and optimize our comprehensive AI-powered toolbox based on the actual needs from our drug R&D programs. We will continuously augment each task on hand with AI tools to eventually create a new drug R&D paradigm.
First, we establish our drug discovery program with new insights about patient unmet needs and disease mechanisms.
Second, we build a needs-driven AI technology platforms to enable the design and development of new drugs.
Our initial focus area is immunology. Immunological disorders, particularly autoimmune diseases, are many (over 100 different types of autoimmune diseases) and with large unmet needs. The autoimmune disease treatment market potential is very attractive. The global market for the autoimmune disease treatments was over $100 billions and expeted to $163.8 billions by 2030. The field of autoimmune diseases will be a fertile ground for the development of new drugs due to the rapid advancement of our understanding of diseases in the space.
They are highly heterogeneous with large variability among different patient sub-population
They are often caused by multiple factors
They are mostly manifested locally
To better stratify the patients and identify the underlying dysfunctional targets
To design a drug with better selectivity and specificity
To design a drug that addresses the local problem without disrupting the systemic immune balance
To design a drug that can engage multiple targets synergistically
To significantly improve the druggability and the success rate of clinical outcome for the design molecule